We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Clinical Study of Spinal Muscular Atrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00443066
Recruitment Status : Completed
First Posted : March 5, 2007
Last Update Posted : March 21, 2023
The Spinal Muscular Atrophy Foundation
Information provided by (Responsible Party):
Columbia University

Tracking Information
First Submitted Date March 1, 2007
First Posted Date March 5, 2007
Last Update Posted Date March 21, 2023
Study Start Date May 2005
Actual Primary Completion Date August 17, 2011   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: February 12, 2013)
  • Hammersmith Functional Motor Scale Expanded (HFMSE) [ Time Frame: Up to 36 months ]
    For SMAII/III patients over 2 years of age, we will additionally administer the Hammersmith SMA functional motor scale (H-SMA-FMS), a disease-specific instrument.
  • Gross Motor Function Scale (GMFM) [ Time Frame: Up to 36 months ]
    The GMFM contains 88 items in 5 dimensions: (A) lying and rolling, (B) sitting, (C) crawling, (D) standing, and (E) walking.
Original Primary Outcome Measures Not Provided
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title Clinical Study of Spinal Muscular Atrophy
Official Title Clinical Study of Spinal Muscular Atrophy
Brief Summary

The investigators propose to prepare for clinical trials where SMA patients are asked to join the research effort. The visits will include questions, physical exam, blood drawing, and sometimes X-rays and a skin biopsy. The investigators will use modern computer methods to process the information during which the investigators will plan a clinical trial. Once the clinical trial begins, the investigators will offer SMA patients participation if they meet the criteria for that trial.

Identifying an effective SMA treatment is very important because there is currently none. Clinical trials are the only way to decide whether a new treatment works in SMA patients or not.

Detailed Description

Spinal Muscular Atrophy (SMA) is one of the most devastating neurological diseases of childhood. Affected infants and children suffer from progressive muscle weakness caused by degeneration of lower motor neurons in the spinal cord and brainstem. Clinically, four phenotypes are distinguished within the continuous spectrum of disease severity based on the age of onset and the highest motor milestone ever achieved. SMA is caused by homozygous deletion of the survival motor neuron-1 (SMN1) gene. A related gene, SMN2, produces low levels of full-length SMN protein due to inefficient splicing. There is an inverse correlation between SMN copy number and disease severity, presumably mediated by levels of full length SMN protein. Therefore, increasing the amount of full-length SMN protein is a promising treatment strategy. Several drugs targeting splicing efficiency have resulted in increased SMN protein in preclinical assays and are now awaiting clinical testing.

With the future objective to conduct clinical trials in SMA, the proposed project has 3 specific aims: 1) To establish a web-based database that will serve to enroll the patient population and that will facilitate timely recruitment for future clinical trials; (2) to plan for clinical trials by a) developing reliable outcome measures, and (b) establishing the infrastructure needed to carry out efficient clinical trials, (c) convening meetings of preclinical and clinical researchers involved in SMA drug development to select candidate drugs, and (3) to characterize the patient population from a clinical and molecular point of view.

Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples With DNA
blood and skin tissue
Sampling Method Non-Probability Sample
Study Population People diagnosed with Spinal Muscular Atrophy types I, II, or III before the age of 17.
Condition Spinal Muscular Atrophy
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: April 18, 2011)
Original Enrollment
 (submitted: March 1, 2007)
Actual Study Completion Date August 17, 2011
Actual Primary Completion Date August 17, 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria

  • Clinical diagnosis of Spinal Muscular Atrophy
  • Genetic diagnosis of SMN gene deletion
  • Parents or if applicable subjects must give informed consent
  • must be capable of complying with the study procedures
  • Female subjects of child-bearing potential must agree to undergo pregnancy test prior to radiological studies
  • Diagnosis of SMA before age 19 years

Exclusion Criteria:

  • Unstable medical condition precluding participation
  • Significant respiratory compromise that would interfere with safe travel to site of evaluation. (The clinical site PI decides when air travel is not recommended and when the patient's location is not within a reasonably safe driving distance (upper limit 150-250 miles)
Sexes Eligible for Study: All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
Administrative Information
NCT Number NCT00443066
Other Study ID Numbers AAAB1635
CU52029001 ( Other Identifier: SMA )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD: No
Current Responsible Party Columbia University
Original Responsible Party Not Provided
Current Study Sponsor Columbia University
Original Study Sponsor Same as current
Collaborators The Spinal Muscular Atrophy Foundation
Principal Investigator: Darryl C De Vivo, MD Columbia University
PRS Account Columbia University
Verification Date March 2023